latest news releases from the newsroom
Active Biotech Presents Survival Data on Cancer Drug
STOCKHOLM, Sweden, Sept. 29, 2005 (PRIMEZONE) -- Survival data for renal patients and the first generation (TTS CD2) of ANYARA will be presented at the NCRI (National Cancer Research Institute) conference held in Birmingham, UK, October 2-5.Forty-three renal cancer patients, included in a previously concluded multi-centre open label Phase II study (1) of Active Biotech's TTS CD2, were treated with individualized doses of TTS CD2. All patients were followed for survival and two year survival data have now been compiled.
Active Biotech: Confirmed ANYARA Tumor PET Localization in Cancer Patients
STOCKHOLM, Sweden, Sept. 29, 2005 (PRIMEZONE) -- In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed.Using Positron Emission Tomography (PET) and radioactively labeled ANYARA, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating that ANYARA localizes to tumors that express the target antigen 5T4. The study is ongoing at Paterson Institute for Cancer Research and at Christie Hospital, Manchester, UK and the first results from this study will be presented at the NCRI (National Cancer Research Institute) conference held in Birmingham, UK on October 2-5.
Federal Home Loan Bank of Cincinnati
FHLBank Cincinnati's Third-Quarter Dividend Approved
CINCINNATI, Sept. 29, 2005 (PRIMEZONE) -- The Federal Housing Finance Board's Office of Supervision today approved a third-quarter dividend of 4.875 percent per annum for the period July 1, 2005 to September 30, 2005, unchanged from the second quarter. This dividend will be paid in the form of additional shares of capital stock on September 30, 2005.